Tyra Biosciences, Inc. $TYRA Shares Bought by AlphaQuest LLC

Key Points

• AlphaQuest LLC has significantly increased its stake in Tyra Biosciences, Inc. by 489.7% during Q1, now owning approximately 29,622 shares valued at $275,000.
• Insider activity shows that Director Gilla Kaplan sold 30,000 shares for $309,300, reducing their ownership by approximately 33.47%.
• Equities analysts generally have a "Buy" rating on Tyra Biosciences, with an average target price of $30.83, indicating potential growth for investors.

AlphaQuest LLC lifted its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 489.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,622 shares of the company's stock after buying an additional 24,599 shares during the period. AlphaQuest LLC owned approximately 0.06% of Tyra Biosciences worth $275,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in TYRA. Boxer Capital Management LLC acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth about $28,185,000. Farallon Capital Management LLC acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth about $13,914,000. Vestal Point Capital LP acquired a new stake in shares of Tyra Biosciences during the fourth quarter worth about $13,761,000. Orbimed Advisors LLC boosted its stake in shares of Tyra Biosciences by 91.3% during the fourth quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company's stock worth $20,434,000 after buying an additional 701,448 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in Tyra Biosciences by 63.6% during the fourth quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company's stock worth $24,291,000 after purchasing an additional 679,124 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on TYRA shares. Piper Sandler started coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Friday, August 22nd. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Tyra Biosciences has a consensus rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Trading Down 1.3%

Shares of TYRA stock traded down $0.16 during trading hours on Tuesday, hitting $12.51. The company's stock had a trading volume of 290,093 shares, compared to its average volume of 301,478. The business has a fifty day moving average of $10.73 and a 200-day moving average of $10.27. The stock has a market cap of $666.73 million, a price-to-earnings ratio of -7.04 and a beta of 1.09. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $29.60.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.06. On average, equities analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In other Tyra Biosciences news, Director Gilla Kaplan sold 9,568 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $9.78, for a total value of $93,575.04. Following the completion of the sale, the director directly owned 28,231 shares of the company's stock, valued at approximately $276,099.18. The trade was a 25.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 61,392 shares of company stock valued at $628,358. 15.20% of the stock is currently owned by insiders.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.